Theravance Biopharma Highlights Q1 2026 Ampreloxetine Phase 3 Data, Strong YUPELRI Sales, and $175M in Milestones

summarizeSummary

Theravance Biopharma presented a strong investment case, highlighting a major Q1 2026 Phase 3 data readout for Ampreloxetine, substantial upcoming sales milestones, and a robust financial position with growing YUPELRI sales.

check_boxKey Events

• Ampreloxetine Phase 3 Data Expected

  Topline data from the pivotal Phase 3 CYPRESS trial for Ampreloxetine, targeting symptomatic nOH in MSA, is anticipated in Q1 2026. The company is preparing for an expedited NDA filing if results are positive.

• Substantial Milestones Anticipated

  Theravance Biopharma is on pace to achieve $150 million in TRELEGY sales-based milestones and a $25 million YUPELRI sales milestone in 2025-2026, providing significant non-dilutive capital.

• Strong Financial Position

  The company achieved non-GAAP breakeven in Q3 2025 and reported $332.7 million in cash and cash equivalents with no debt as of September 30, 2025.

• YUPELRI Sales Growth

  U.S. net sales for YUPELRI increased 15% year-over-year to $71.4 million in Q3 2025, with hospital doses growing 29% and achieving a new hospital market share high of 21%.

auto_awesomeAnalysis

This corporate presentation outlines a highly positive outlook for Theravance Biopharma, driven by a critical near-term clinical catalyst, robust commercial performance, and significant non-dilutive cash inflows. The upcoming Q1 2026 Phase 3 data for Ampreloxetine in neurogenic orthostatic hypotension (nOH) due to Multiple System Atrophy (MSA) represents a major value inflection point for a potential first-in-class therapy targeting a rare disease. The company's strong financial position, marked by achieving non-GAAP breakeven in Q3 2025 and holding $333 million in cash with no debt, provides a solid foundation. Furthermore, the expectation of $175 million in highly probable milestones from TRELEGY and YUPELRI sales in 2025-2026 significantly enhances the company's financial flexibility and reduces future funding risk. Continued growth in YUPELRI net sales further underscores the commercial strength of its approved product.